Page 3 - Program On Regulation News Today

Shortages, cost, and delays may reduce the effectiveness of CAR-T treatment and increase the risk of patient mortality in multiple myeloma.

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and...

This Viewpoint discusses how limited-supply agreements (introduction of generic products in reduced volumes) might thwart efforts to negotiate lower prices on p

This Viewpoint looks at the lawsuits brought by pharmaceutical companies to challenge the Inflation Reduction Act of 2022, in particular claims under the First

Early next year, the chain will start producing a cheaper version of Humira, with other meds to follow. Heres what to know about biosimilar drugs.

After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less.

After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less.

After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less.

All medicines with marginal effectiveness and worrisome side effects should be used sparingly until better evidence is collected.

Study finds no difference in revenue between drugs for rare diseases and the general population